Iron deficiency is a common comorbidity in heart failure (HF), with a prevalence of up to 55% in chronic HF, and up to 83% in acute decompensated HF [1]. It is an independent predictor of poorer prognostic outcomes in HF and is associated with a worse quality-of-life (QoL) and exercise capacity, as well as increased risk of hospitalization, regardless of anemia status [[2], [3], [4], [5], [6]].

International guidelines for treating HF, such as the American Heart Association /American College of Cardiology/Heart Failure Society of America 2022 guidelines [7], European Society of Cardiology (ESC) 2021 guidelines and 2023 update [8,9], and the Asian Pacific Society of Cardiology (APSC) consensus statements [10] have provided recommendations for the management of iron deficiency in HF, but local guidelines in Asia are not as well-established, and practical use of guidelines for management of iron deficiency is limited in the region. The procedures for management of iron deficiency are not standardized across Asia and there is a paucity of clinical data [11], leading to inadequate awareness and treatment of this condition. Hence, a group of experts in Asia convened to discuss clinical gaps, and to provide recommendations to general physicians and cardiologists regarding the screening, treatment, and monitoring of iron deficiency in patients with HF to optimize clinical outcomes in the region.